5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis

Non–Small Cell Lung Cancer

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5

(2015) Jun-jie Chen et al.   Oncotarget

H-Ras regulation of TRAIL death receptor mediated apoptosis

(2015) Jun-Jie Chen et al.   Oncotarget

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity

(2014) H. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the RAS oncogene

(2013) Asami Takashima et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators

(2013) Yuanxiang Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Transcriptional regulation of the survivin gene

(2013) Romain Boidot et al.   MOLECULAR BIOLOGY REPORTS

The Synergistic Effects of Low Dose Fluorouracil and TRAIL on TRAIL-Resistant Human Gastric Adenocarcinoma AGS Cells

(2013) Hong Zhu et al.   Biomed Research International

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

(2012) L Y Dimberg et al.   ONCOGENE

Lung-Cancer Chemoprevention by Induction of Synthetic Lethality in Mutant KRAS Premalignant Cells In Vitro and In Vivo

(2011) S. Huang et al.   Cancer Prevention Research

Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling

(2011) You-Take Oh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

5-Fluorouracil Increases the Chemopreventive Potentials of Resveratrol Through DNA Damage and MAPK Signaling Pathway in Human Colorectal Cancer Cells

(2011) Purusottam Mohapatra et al.   ONCOLOGY RESEARCH

ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis

(2010) Venturina Stagni et al.   CARCINOGENESIS

Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation

(2010) Annie Yang et al.   CURRENT OPINION IN CELL BIOLOGY

Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells

(2010) C. Haag et al.   GUT

Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis

(2010) Ling Zhang et al.   NATURE

Is TRAIL the holy grail of cancer therapy?

(2009) Thomas Newsom-Davis et al.   APOPTOSIS

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY